ClinicalTrials.gg
Not yet recruitingNCT07448415Updated Mar 4, 2026

Evaluation of the Efficacy of Oral Tranexamic Acid and Glutathione-assisted Microneedling in Treatment of Melasma

A Phase 2/3 interventional study of microneedling and Oral tranexamic acid in Melasma, sponsored by Assiut University. Not yet recruiting. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Assiut University · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing Tranexamic Acid in Melanosis — 6 open to participants now, 7 under way, 2 of them phase 3. Tranexamic Acid · Melanosis.

Planned enrollment
11th of 16
42 · median 52
Started
2026
with 2 others
Phase 2/3
2 of 16
1 open now
Registered
14th of 16
by date
Lead sponsor
2 of 16
Assiut University

Among the 16 studies testing Tranexamic Acid in Melanosis, this one is the 11th largest by planned enrollment, is one of 3 that started in 2026, is one of 2 in phase 2/3, and was the 14th registered.

Melanosis

170 studies on the registry are indexed under Melanosis; 46 are open to participants now.

Browse Melanosis studies →

Open to participants now

6 of the 16 studies testing Tranexamic Acid in Melanosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 19 Melanosis studies recruiting now, 8 (42%) set no upper age limit and 11 (58%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing Tranexamic Acid in Melanosis, or all of them as a file.
02

Study summary

In this study, the investigators evaluate the potential efficacy of TXA alone and microneedling assisted with glutathione alone versus combination of oral tranexamic acid and glutathione-assisted microneedling in the treatment of melasma

Read the detailed description

Melasma is a chronic, acquired, frequent relapsing and cosmetically disfiguring disorder of hypermelanosis, characterized by light to dark brown hyperpigmentation mostly in sun exposed areas, affected predominantly middle aged females particularly those with darker skin, multiple factors have been postulated to involve in the etiology and pathogenesis of melasma like ; pregnancy, genetics, sun exposure and skin inflammation .Melasma significantly affect quality of life and self-steem of the patients due to its disfigurity appearance.

Although melasma has been widely studied, the treatment still met with difficulty, various therapeutic approaches were tried in treatment of melasma including topical and systemic treatments, chemical peeling, and laser therapy, however none have shown sustained results with incomplete clearance and frequent recurrences.

There has been interest lately in oral medications like tranexamic acid (TXA ) to improve melasma, oral TXA is a synthetic derivative of the amino acid lysine, lysine is an antifibrinolytic agent, procoagulant and approved by FDA for the treatment of cyclic heavy menstrual bleeding, oral TRX acid has been used off-label in dermatology for treatment of hyperpigmentation disorders

.

Also glutathione(GSH) is an option in treatment of melasma, GSH is endogenous tripeptide composed of cysteine, glycine, and glutamate, and serves as a key component of the cellular antioxidant defenCe system by scavenging free radicals and reducing oxidative stress it is considered as skin lightening agent, its major mechanism by inhibition of tyrosinase, tyrosinase inhibition effect indirectly as anti-oxidant agent.

Microneedling is a well-known and established approach for drug delivery applied to treat various skin issues, including melasma. Existing studies indicate that microneedling is an effective adjuvant topical therapy for melasma.

03

Conditions studied

  • Melasma

Browse trials for

Keywords

  • Tranexamic acid
  • glutathione
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • female patients

      • 18/50 years old
      • facial melasma

Exclusion criteria

Exclusion Criteria:

  • pregnancy
  • lactation.
  • History of any bleeding,
  • clotting disorder
  • using anticoagulants
  • Chronic systemic diseases
  • patients with history of atypical parkinsonism
  • use of neuroleptics,
  • history of a seizure
  • drug addiction
  • Patients with signs of facial inflammation or infection.
  • Patients on oral pills
  • patients with hormonal replacement therapy
  • patients on isotretinoin at the time of the study or during the past 6 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Active comparator
    Combined TXA + GSH-assisted microneedling arm

    will include 14 patients with facial melasma. They will be treated by combined * oral tranexamic acid (250 mg) twice a day for 3 months * microneedling assisted with glutathione every 4 weeks for a maximum of 3 months.

    Device: microneedling · Drug: Oral tranexamic acid · Other: Glutathione

  • Active comparator
    GSH-assisted microneedling arm

    will include 14 patients, they will be treated by microneedling assisted with glutathione every 4 weeks for a maximum of 3 months.

    Device: microneedling · Other: Glutathione

  • Active comparator
    Oral TXA

    will include 14 patients, they will be treated by * oral TXA alone 250mg twice daily for a maximum of 3 months.

    Drug: Oral tranexamic acid

Interventions

  • Devicemicroneedling

    with one ml of topical glutathione will be done in group A and B, three consecutive sessions, will be performed by derma pen with 36 needles head, will adjusted 1.5 mm needle length and will moved on stretched skin in four directions several times till erythema and pinpoint developed before and after topical application of GTH.

  • DrugTranexamic AcidStudies of Tranexamic AcidTranexamic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The patient will take oral tranexamic acid 250mg twice daily for 3 months

  • OtherGlutathione

    investigators will use topical GSH solution in assist with microneedling to treat melasma

06

What researchers measure

Primary outcomes

  1. compare reduction of Melasma Area and Severity Index (MASI) score in any treatment modalities

    Time frame: From baseline to 12 weeks

Secondary outcomes

  1. identify patient's satisfaction by Patient Self Assessment

    Time frame: from baseline to 3 months after treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for Feb 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2026
First posted
Mar 4, 2026
StartEst.
Feb 2026
Primary completionEst.
Feb 2027
CompletionEst.
Apr 2027
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07448415
Lead sponsor
Assiut University
Responsible party
Rana Sameer Mohamed (Assistant lecturer, Assiut University) — Principal investigator
First posted
Mar 4, 2026
Start date
Feb 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Mar 4, 2026

Study contacts

Rana Sameer, Postgraduate student
Contact
Ranasamer3344@gmail.com
+201064123736

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion